Skip to main content

Table 2 Recently published clinical studies of three leading hemoglobin-based oxygen carriers

From: Hemoglobin-based oxygen carriers

 

Product name

Details

PolyHeme®

Hemopure® (HBOC-201)

HemoLink™ (Hb-raffimer)

Company

Northfield Laboratories (Evanston, IL, USA)

Biopure Corporation (Cambridge, MA, USA)

Hemosol Inc. (Ontario, Canada)

Indicated use

Trauma/urgent surgery

Cardiac surgery

Coronary artery bypass graft

Clinical trial status

Phase III

Phase III

Phase II/III

Study design

Multicenter, randomized, double blind

Multicenter, randomized, double blind

Multicenter, randomized, single blind

End-point

Mortality

Transfusion avoidance

Transfusion avoidance

Major findings

PolyHeme increased survival

Hemopure reduced allogeneic red cell transfusion

HemoLink reduced allogeneic red cell transfusion

Current status

Phase III mortality study

Filed BLA

Clinical study suspended pending further analysis

Reference

Gould and coworkers [11]

Levy and coworkers [12]

Hill and coworkers [19]

  1. BLA, Biologic License Application.